Q3 Earnings Forecast for Immunocore Issued By HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Investment analysts at HC Wainwright raised their Q3 2027 earnings estimates for Immunocore in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.39 for the quarter, up from their prior estimate of $0.28. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for Immunocore’s Q4 2027 earnings at $0.49 EPS and FY2028 earnings at $4.53 EPS.

IMCR has been the subject of a number of other research reports. Mizuho increased their price target on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $57.29.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $34.74 on Thursday. The stock’s fifty day simple moving average is $31.95 and its 200 day simple moving average is $31.33. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -93.89 and a beta of 0.74. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. Immunocore has a 52-week low of $27.56 and a 52-week high of $40.71.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The company had revenue of $115.93 million during the quarter, compared to the consensus estimate of $148.57 million. Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently made changes to their positions in IMCR. Harbour Investments Inc. raised its position in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after buying an additional 572 shares during the period. R Squared Ltd boosted its holdings in shares of Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after buying an additional 606 shares during the period. Leonteq Securities AG acquired a new position in Immunocore in the 4th quarter valued at $30,000. Finally, Orion Porfolio Solutions LLC grew its stake in Immunocore by 4.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after buying an additional 1,031 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.